Sirona Biochem Announces Chief Scientific Officer to Present at Adaptations in Polar Environments and Biomimicry
Momentum Public Relations
Press Release: February 2, 2018
Sirona Biochem Corp. (TSX VENTURE: SBM)(FRANKFURT: ZSB)(XETRA: ZSB) (the “Company”) announced today that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy will attend and present at the Paris symposium: Adaptations in Polar Environments and Biomimicry.
The conference showcases animal adaptations to extreme polar environments, and how these adaptations have inspired commercial technology. Dr. Deliencourt-Godefroy will present on February 3rd at 11:00 AM CET, on the glycoproteins that were discovered in Arctic fishes and her advancement of the technology in human cell preservation. Her talk can be streamed live at:
https://cite-sciences.ubicast.tv/permalink/l1253c0f84c1fnr2u6ni/iframe/
NB: the conference is held in French.
About Milieux Polaires et Biomimétisme and Poles Actions
The yearly symposium is organized by Poles Actions and is dedicated to polar biomimicry.
The association of Poles Actions is intended to promote the knowledge and the protection of Arctic and Antarctic ecosystems through awareness, education and support for research in polar and subpolar regions. It acts as a nonpartisan, objective and scientifically credible channel of communication, based on the activities and experience of its members and external stakeholders. It organizes educational interventions, exhibitions, conferences and scientific expeditions to help publicize and protect these fragile ecosystems. For more information, visit: http://www.ourspolaire.org/
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Sirona Biochem
Sirona Biochem Announces Receipt of $500,000 US Milestone Payment
Momentum Public Relations
Press Release: January 29, 2018
Sirona Biochem Corp. (TSX VENTURE: SBM)(FRANKFURT: ZSB)(XETRA: ZSB) (the “Company”) is pleased to announce that the $500,000 USD payment from Wanbang Biopharmaceuticals has been received.
The Company now awaits the China Food and Drug Administration (CFDA) approval of the IND filing, which will lead to a clinical trial of Sirona’s SGLT2 inhibitor for diabetes. The CFDA is required to respond to the submission no later than sixty days after filing. Filing took place December 27th, 2017. The acceptance of the IND application by the CFDA, will trigger another $500,000 USD milestone payment to Sirona Biochem.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Sirona Biochem
Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension
Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension
Momentum Public Relations
Press Release: August 23, 2017
VANCOUVER, BC–(Marketwired – August 23, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces an extension to the term of 8,850,770 common share purchase warrants (the “Warrants”) originally issued on March 6, 2014. The warrants were issued as part of a private placement. The expiry dates will be extended as follows:
March 6, 2014 | |
Number of Warrants: | 8,850,770 |
Original Expiry Date of Warrants: | March 6, 2017 |
New Expiry Date of Warrants: | November 30, 2017 |
Exercise Price of Warrants: | $0.25 |
All other terms of the Warrants will remain unchanged.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, Life Sciences, News Home, Sirona Biochem, Technology
Sirona Biochem Announces Positive Efficacy Results for Skin Lightening Library
Sirona Biochem Announces Positive Efficacy Results for Skin Lightening Library
Momentum Public Relations
Press Release: July 6, 2017
VANCOUVER, BC–(Marketwired – July 06, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB)(XETRA: ZSB) (the “Company“) announced positive preclinical efficacy data for its library of skin lightening compounds.
The study was conducted at Bioalternatives in France, a contract research organization specializing in cellular and molecular pharmacology. The study looked at each of six compounds’ ability to inhibit melanin synthesis induced by L-tyrosine for 10 days in normal human epidermal melanocytes. Results showed a significant decrease in melanin synthesis with a similar efficacy across the library. Inhibiting melanin production is the principal mechanism of action for the majority of skin lighteners in clinical use.
“In December 2016, we announced the completion of our skin lightening library, with plans to begin testing in 2017,” said Dr. Howard Verrico, CEO. “The positive efficacy of these compounds adds value to a licensing transaction as it increases the opportunity for commercialization in various markets and therapeutic areas. Moreover, this data will be used to support and strengthen our IP in this area.”
Sirona has shared these results with the multinational companies currently working towards a license to commercialize TFC-1067.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Life Sciences, News Home, Sirona Biochem
The Fountain of Youth May Be Just Around the Corner In Vancouver
The Fountain of Youth May Be Just Around the Corner In Vancouver
Sirona Biochem makes safer and more effective cosmeceuticals
Vancouver-based Sirona Biochem is on track to crack the global market for skin lightening products, a market that has been predicted by Global Industry Analysts to hit US$23 billion by 2020. If that isn’t enough the company is also developing a product designed to forestall facial aging. Zion Market Research pegs the global anti-aging market at US$216.52 billion by 2021. The Company’s skin lightening products are far safer and far more effective than those which are currently on the market.
In hindsight it is not that surprising that Vancouver is becoming a hotbed of discovery when it comes to turning back the ravages of time. Botox as we know it today for the cosmetics industry, after all, was popularized in Vancouver by the husband and wife team of ophthalmologist Jean Carruthers and dermatologist Alistair Carruthers. They discovered that a toxin named botox helped eradicate the lines and wrinkles caused by aging.
Sirona Biochem Corp. (TSX-V:SBM) is a discovery and development stage biochem company that has developed a proprietary way to treat carbohydrate molecules using fluorination chemistry. This process prevents molecules from breaking down when exposed to enzymes. This now opens the door to developing a new field of therapeutics.
The company also has an anti-aging product based on synthesizing the glycoprotein found in the blood serum of Antarctic water fish and is currently in the testing and validation stage. The glycoprotein helps preserve the fish and its cells from the freezing water. When applied to humans, it helps prevent skin cells from dying, and also protects them from the harsh glare of ultra-violet radiation.
The good news for Sirona, however, doesn’t stop there. The company believes their stabilized carbohydrate molecules have applications in the treatment of cancer, pain, diabetes and inflammation. Sirona has developed an SGLT2 inhibitor as a Type 2 Diabetes treatment. Research and consulting firm Global Data has predicted that the global type 2 diabetes market will almost double from US$31.2 billion in 2015 to US58.7 billion by 2025.
SGLT2 inhibitors are a recent development in the fight against Type 2 diabetes. Most traditional diabetes treatments work by controlling insulin production or regulating blood sugar levels. SGLT2 inhibitors work by acting in the kidneys to reduce the reabsorption of glucose into the bloodstream.
Sirona’s strategy is to do the basic discovery and development work on a given product, and then to license the technique or joint venture it for commercialization, marketing and distribution. In 2014 the company signed a licensing agreement with Wanbang Biopharmaceuticals for the Chinese market. Wanbang will develop and commercialize Sirona’s SGLT2 inhibitor exclusively in the People’s Republic of China. The company also has a licensing agreement with Obagi Medical Products for a skin lightening agent.
Sirona Biochem was founded in 2009 by CEO Dr. Howard Verrico. The first thing Verrico did was to acquire the exclusive global license from TFChem for its proprietary SGLT2 Inhibitor. TFChem is based in Rouen, France. Verrico thought enough of TFChem’s research that he then went on to acquire TFChem as a wholly-owned subsidiary from its founder Dr. Geraldine Deliencourt-Godefroy. She then became Sirona’s Chief Science Officer and largest shareholder. TFChem now acts as Sirona’s research and development laboratory. A respected scientist, Deliencourt-Godefroy has also received a variety of honours in France including the acclaimed Francinov Research and Innovation Medal, the French Ministry of Research Award and the French Senate Award.
The company sees the cosmetic and cosmeceutical industry as its first major market penetration target for two important reasons. The first is that, as noted above, the financial reward for creating a fountain of youth will be immense. Secondly, the amount of regulatory testing for cosmetics is miniscule when compared to that involved in the pharmaceutical industry. The company intends to use the cash flow created by its anti-aging platform and skin colour lightening products, to finance the creation of more traditionally flavoured therapies for things like cell preservation and anti-inflammatories.
The company’s development focus is based on three high-return fields of discovery and development:
- Therapeutics: diabetes, anti-inflammatories and anti-infectives
- Cosmeceuticals: anti-aging and depigmenting agents
- Biological Ingredients: inducers and adjuvants for biological development and preservation.
With an SLGT2 inhibitor in the pre-clinical stage and four cosmetic products in the testing and validation phase, the company has received revenues and will continue to do so in the future from Wanbang for its SLGT2 inhibitor. Sirona also receives revenue from Obagi Medical products for a skin lightener, one of three skin lightening agents under development. It is also working on an acne treatment, an anti-inflammatory and an anti-infective.
Much of Sirona’s work is ground-breaking. Stabilizing carbohydrate molecules opens up new fields for therapeutic interventions and may rejuvenate older treatments which became stalled. Synthesizing the glycoprotein found in the blood serum of Antarctic fish may produce a product that slows down the aging of skin. One way to illustrate its potential value is that when TFChem first synthesized the glycoprotein, cosmetic giant L’Oreal Group, the world’s largest cosmetics company slapped a field-of-use patent on it. As it turns out the first synthesis was not stable, but the later ones were, and L’Oreal was out of luck.
While Sirona is concentrating on developing cosmetic products, it hasn’t neglected the medical side of things. The company has a pipeline of products that are heading towards the market. The anti-aging compound is now in the testing and validation phase.
The company has a 52-week high of $0.20 and a 52-week low of $0.12. As of June 16, 2017, it was trading at $0.17. And if you were wondering, Sirona is the name of the Celtic goddess of healing.
- Published in Bio technology, Blog, Sirona Biochem, Technology
Sirona Biochem Closes Convertible Note Financing
Sirona Biochem Closes Convertible Note Financing
Momentum Public Relations
Press Release: June 5, 2017
VANCOUVER, BC–(Marketwired – June 05, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB)(XETRA: ZSB) is pleased to announce that it has closed the non-brokered private placement (the “Private Placement”) of convertible notes (“Notes”). The financing was oversubscribed, resulting in gross proceeds of $587,000. Each Note is convertible at the option of the holder into one common share of the company at a conversion price of $0.18 per share.
The Notes will mature in 18 months from the date of issuance and bear interest at the rate of 12{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} per annum, payable quarterly, until the Notes are converted or repaid. The company will be entitled to repay the principal amount of the Notes, together with accrued and unpaid interest, at any time commencing four months after the date of issuance, subject to giving the holders prior notice thereof to permit holders to convert during the notice period.
All securities issued in connection with the private placement will be subject to a statutory hold period expiring on October 5, 2017.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: a third party potential licensees of TFC-1067 may not deliver a term sheet to the company in Q1 2017 or at all; the company may not be able to negotiate a license agreement with a potential licensees of TFC-1067 on terms acceptable to Sirona Biochem; the progress and timing of its clinical trials are uncertain; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing products; unexpected adverse side effects or inadequate therapeutic efficacy of the company’s or licensed products that could delay or prevent product development or commercialization; the scope and validity of patent protection for the company’s or licensed products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, News Home, Sirona Biochem, Technology
Target Price for Sirona Biochem (SBM:tsxv) 0.98$
Sirona Biochem (SBM:tsxv) Gets BUY Rating : Target Price CAD 0.98$
– Momentum Public Relations –
Yesterday, First Berlin Equity Research published a research update on Sirona Biochem Corp. (SBM:tsxv). Analyst Ellis Acklin reiterated his BUY rating and increased the price target from CAD 0.90 to CAD 0.98.
This is an abbreviated summary. The full text of this story (including disclosure) is included below.
Abstract:
Sirona Biochem Corp. (Sirona) published annual results for the year ended 31 October 2015. Results were largely in line with our forecasts. The company continues to communicate confidence in the signing of a new agreement for its promising skin lightening treatment TFC-1067. We see this as a potential watershed event for the company. Potential upfront, milestone and royalty payments harbour significant upside for Sirona once a deal is sealed. After recalibrating our forecasts and model, we raise our price target to C$0.98 (previously: C$0.90) and reiterate our Buy rating.
Financial Forecasts: |
2013 |
2014 |
2015 |
2016E |
2017E |
2018E |
Revenue (CADm) |
0.00 |
0.21 |
0.01 |
0.38 |
8.79 |
21.45 |
EBIT (CADm) |
-2.64 |
-3.48 |
-3.48 |
-3.20 |
5.13 |
17.69 |
EPS (diluted) (CAD) |
-0.03 |
-0.03 |
-0.03 |
-0.01 |
0.02 |
0.07 |
FCF (CADm) |
-2.62 |
-2.09 |
-3.18 |
-2.88 |
2.76 |
10.88 |
http://www.slideshare.net/MomentumPR/first-berlin-equity-research-sbmtsxv
- Published in Blog, Life Sciences, Sirona Biochem
Sirona to Attend Cosmetic360 Conference in Paris
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) announces that it will attend Cosmetic360 in Paris, France, October 15-16, 2015. Cosmetic360 is an innovative trade forum for the cosmetic industry. The conference brings together professionals and industry representatives from all over the world. All facets of the cosmetic industry are represented at the conference including, raw materials, formulation, packaging, testing and analysis, finished products, and distribution. More information on the conference can be found at http://www.cosmetic-360.com/en.
Cosmetic360 provides Sirona Biochem an opportunity to introduce its skin lightening compound SBM-TFC-1067 and cell preservation compound SBM-TFC-837 to industry professionals, international cosmetic company representatives, and other interested parties. The Company will participate in open innovation meetings organized with top cosmetic companies, including L’Oréal, J&J, LVMH, Channel, Boots, and Shiseido. The Company will also be connecting with other companies and representatives in the cosmetic industry at its booth at the conference.
At the conference, Sirona Biochem is entering its cell preservation compound SBM-TFC-837 in the international competition for innovations, “The Cosmetic Victories”. This is a unique competition of projects in the planning or development stage. The jury adjudicating the competition, composed of representatives from top names in the cosmetic industry, will select the most innovative projects and may also become involved in their development.
Dr. Howard Verrico, the Company’s CEO stated, “We are excited to be participating in Cosmetic360. The conference will provide valuable exposure for Sirona and our therapeutic compounds. While we have already been in discussions with several multi-national companies, we hope to promote Sirona to a wider audience at the conference and reach out to new potential partners and contacts.”
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety.
Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
- Published in Blog, Business, Life Sciences
Sirona Biochem (SBM:tsxv) Investor Event
Sirona met with Investors and Brokers at Canaccord in Vancouver on September 15th, 2015.
This is the most recent corporate presentation that was put together for this recent Investor Event. You will find current collaborations, what they have in the pipeline, and the revenue growth potential.
Sirona’s presentation also reveals why management is so excited about its next major transaction.
Sirona Biochem Corp. is a biotechnology company with an innovative platform of fluorination chemistry technology. This platform is used to develop safer, more effective cosmetic and pharmaceutical active ingredients, which are licensed to partners in exchange for upfront, milestone and royalty payments. Sirona’s pipeline has produced licensing deals with Valeant Pharmaceuticals and Fosun Pharma.
- Published in Blog, Life Sciences
Sirona’s Partner Completes SBM-TFC-039 Toxicology Test
Positive Preclinical Toxicology Results for its SGLT2 Inhibitor Trigger Milestone Payment from Wanbang Biopharmaceuticals
Sirona Biochem Corp. (TSX VENTURE: SBM) today announced that Wanbang Biopharmaceuticals has successfully completed the toxicology study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 diabetes.
In the study, SBM-TFC-039 was orally administered to Sprague Dawley (SD) rats for 14 days to evaluate safety and simultaneously observe toxicokinetics. Dosing of SBM-TFC-039 was either 0, 100, 300 or 800 milligrams per kilogram per day (mg/kg/day) as well as 300 mg/kg/day of the reference drug Canagliflozin.
The results of the study demonstrated that the maximum tolerated dose (MTD) of SBM-TFC-039 was greater than 800 mg/kg/day, which was significantly greater than the 300 mg/kg/day of the Canagliflozin reference. There was no mortality in the groups treated with SBM-TFC-039 and the histopathology showed no visual abnormalities.
The reference drug Canagliflozin is Johnson and Johnson’s SGLT2 inhibitor for type 2 diabetes. It was the first SGLT2 inhibitor launched and it has been on the market in many countries including the United States since 2013. Sales in 2013 were $150 million and in 2014 were $622 million. Sales forecasts for this year are $1 billion.
The completion of this test will trigger a milestone payment to Sirona from Wanbang Biopharmaceuticals as part of the $9.5M in upfront and milestone payments.
“The results of the toxicology study are very encouraging. They provide the preclinical validation to proceed to second line testing which comprises of additional safety and tolerability testing with pharmacokinetics. This is the last step required before moving towards investigational new drug (IND) status in humans”, said Attila Hajdu, Chief Business Development Officer of Sirona Biochem.
About Wanbang Biopharmaceuticals
Wanbang Biopharmaceuticals is the leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Biopharmaceuticals is one of the largest manufacturers and marketers of a comprehensive portfolio of drugs for diabetes. Wanbang Biopharmaceuticals is a subsidiary of Shanghai Pharmaceutical Group which is listed on the Shanghai Stock Exchange. Fosun Pharma, one of the major shareholders of Sinopharm Group, the largest drug distributor in China, is part of Fosun International, the leading non-state owned enterprise group in China which is listed on the Hong Kong Stock Exchange.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com
- Published in Blog, Life Sciences
- 1
- 2